Biotech News

Personalis Reports Third Quarter Results

Personalis (PSNL)PersonalisEarnings

Reports Q3 clinical test volume of 13,157, clinical revenue of $4.4 million and overall revenue of $25.6 million FREMONT, Calif. --(BUSINESS WIRE)--Nov. 4, 2026-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results

Related news

Personalis

Precision-Oncology Genomics Personalis develops genomic tests for cancer detection, monitoring and therapy development. Its platform uses highly sensitive sequencing and tumor-informed analysis to identify minimal residual disease. NeXT Personal NeXT Personal is a personalized circulating-tumor-DNA test designed to detect and track...

Recent company news

Stock data

Close
14.72 USD
Market cap
1.17B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States